New Lung Cancer Drugs Raise Hope for Mesothelioma Patients

The U.S. Food and Drug Administration (FDA) recently granted approval for immunotherapy drugs Keytruda and Opdivo to fight non-small cell lung cancer, raising the hopes of patients with malignant pleural mesothelioma. Drugmakers Merck &Co. and Bristol-Myers Squibb manufacture Keytruda (pembrolizumab) and Opdivo (nivolumab), respectively. Both drugs target PD-1 and PD-L1, specific proteins that block a body's immune system from attacking the cancer cells. Those same proteins were identified in a subset of mesothelioma patients with the shortest survival times. The University of Chicago Comprehensive Cancer Center recently started the only phase II mesothelioma clinical trial for Keytruda. Meanwhile, the Netherlands Cancer Institute in Amsterdam announced in July the first mesothelioma clinical trial for Opdivo. Both drugs were already approved for other cancers, and they are now being tested in numerous clinical trials across the U.S. Opdivo has shown a promising response rate with cancers of the bladder, kidney, head and neck. Immunotherapy Cancer Drugs Work Best in Synergy Cancer researchers believe that immunotherapy drugs, such as Keytruda and Opdivo, can be utilized most effectively in a combined effort, also known as synergy, with other drugs as adjuvant treatment to eliminate remaining cancer cells after surgery. For example, the FDA approved Opdivo in 2014 for use in combination with Yervoy, a skin cancer drug, as an immunotherapy strategy for advanced mel...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Publication date: Available online 20 October 2018Source: Journal of Molecular Graphics and ModellingAuthor(s): Süleyman Selim Çınaroğlu, Emel TimuçinAbstractReplication Protein A (RPA) mediates DNA Damage Response (DDR) pathways through protein-protein interactions (PPIs). Targeting the PPIs formed between RPA and other DNA Damage Response (DDR) mediators has become an intriguing area of research for cancer drug discovery. A number of studies applied different methods ranging from high throughput screening approaches to fragment-based drug design tools to discover RPA inhibitors. Although these method...
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
Publication date: Available online 21 October 2018Source: Life SciencesAuthor(s): Ivan Mrkić, Rajna Minić, Dragan Popović, Irena Živković, Marija Gavrović-JankulovićAbstractAimTo investigate the immunomodulatory potential of a chimera composed of the receptor-binding domain of hemagglutinin 1 (H1s) from Influenza virus and Der p 2 (D2) allergen for allergen-specific immunotherapy of house-dust mite allergy (HDM).Main methodsH1sD2 chimera and D2 allergen were produced by genetic engineering in E. coli. Recombinant antigens were extracted from inclusion bodies by urea, then refolded and purified by immobilized- metal ...
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 21 October 2018Source: Journal of Theoretical BiologyAuthor(s): Claude Gérard, Didier Gonze, Albert GoldbeterAbstractA network of cyclin-dependent kinases (Cdks) regulated by multiple negative and positive feedback loops controls progression in the mammalian cell cycle. We previously proposed a detailed computational model for this network, which consists of four coupled Cdk modules. Both this detailed model and a reduced, skeleton version show that the Cdk network is capable of temporal self-organization in the form of sustained Cdk oscillations, which correspond to the orderly pr...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
Publication date: Available online 21 October 2018Source: American Journal of Preventive MedicineAuthor(s): Soham Gupta, Alexander P. Cole, Maya Marchese, Ye Wang, Jacqueline M. Speed, Sean A. Fletcher, Junaid Nabi, Sebastian Berg, Stuart R. Lipsitz, Toni K. Choueiri, Steven L. Chang, Adam S. Kibel, Annemarie Uhlig, Quoc-Dien TrinhIntroductionWith improvements in early detection and treatment, a growing proportion of the population now lives with a personal history of a cancer. Although many cancer survivors are in excellent health, the underlying risk factors and side effects of cancer treatment increase the risk of medic...
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
ConclusionPD-1/PD-L1 pathway was expressed in MTC patients and was significantly correlated with the distant metastases at surgery, which may shed light on PD-1/PD-L1 as a promising therapeutic target in MTC. Future better understanding of PD-1/PD-L1 expression and their relationship with immunotherapy response may provide direct evidence for management of refractory MTC.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Whole-breast radiation therapy can significantly lower the risk of recurrent...Read more on AuntMinnie.comRelated Reading: Can dedicated breast PET identify suspicious lesions? Women still need breast imaging after mastectomy Is radiation therapy warranted for DCIS postlumpectomy? Microbubbles improve breast cancer radiation therapy ASTRO: Short radiation course safe for breast cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
The objective of this study was to investigate canine gliomas for the IDH1 R132H point mutation using immunohistochemistry. Thirty-one formalin-fixed and paraffin wax-embedded canine gliomas were examined for both IDH1 R132H expression and pan-IDH1 (IDH1 wild-type and point mutated IDH1). Glial tumour specimens were recorded to be either positive or negative for expression. Pan-IDH1 expression was identified in all 31 tumours (100%), while the IDH1 R132H point mutation was identified in none of the tumours (0%). Therefore, the IDH1 R132H point mutation was not identified in this population of canine gliomas and may not be ...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
Authors: Buchanan T, Mutch D Abstract INTRODUCTION: Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly encountered vulvar carcinomas based on the most recent available literature. Areas covered: The clinical environment of squamous cell vulvar cancers are illustrated in order to describe the potential pitfalls and limitations of treatment. Then, by examining publish...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
A larger, weekly dose of radiation therapy has side effects that are comparable...Read more on AuntMinnie.comRelated Reading: Can dedicated breast PET identify suspicious lesions? Women still need breast imaging after mastectomy Is radiation therapy warranted for DCIS postlumpectomy? Microbubbles improve breast cancer radiation therapy ASTRO: Short radiation course safe for breast cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
s P Abstract Besides providing the majority of ATP production in cells, mitochondria are also involved in many other cellular functions and are central for cellular stress signaling. Mitochondrial dysfunction induces not only inherited mitochondrial disorders but also contributes to neurodegenerative diseases, cancer, diabetes, and metabolic syndrome. The HSP60/HSP10 molecular chaperone complex facilitates folding of mitochondrial proteins and is thus an important factor for many mitochondrial functions. To model different degrees of oxidative stress and mitochondrial dysfunction we here describe a HEK293 derived ...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
More News: Asbestosis | Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Colorectal Cancer | Environmental Health | Food and Drug Administration (FDA) | Head and Neck Cancer | Immunotherapy | Lung Cancer | Melanoma | Merck | Mesothelioma | Non-Small Cell Lung Cancer | Skin | Skin Cancer | Study | University of Pennsylvania | Urology & Nephrology | Yervoy